We’re committed to giving you all the clinical information about Tresiba® you need to help your patients. The links below will provide you access to the published clinical data on PubMed.gov, the website of the US National Library of Medicine, National Institutes of Health.
Clinical studies and abstracts

Marso et al 2017 (DEVOTE)
Efficacy and safety of degludec versus glargine in type 2 diabetes
Marso SP, McGuire DK, Zinman B, et al. N Engl J Med. 2017;377(8):723-732.


Zinman et al 2012 (BEGIN: Once Long)
Insulin-naïve adults with type 2 diabetes on Tresiba®, 52-week study
Zinman B, Philis-Tsimikas A, Cariou B, et al; on behalf of the NN1250-3579 (BEGIN Once Long) Trial Investigators. Diabetes Care. 2012;35(12):2464-2471.


Heller et al 2012 (BEGIN: Basal-Bolus Type 1)
Adults with type 1 diabetes converting to Tresiba®, 52-week study
Heller S, Buse J, Fisher M, et al; on behalf of the BEGIN Basal-Bolus Type 1 Trial Investigators.
Lancet. 2012;379(9825):1489-1497.


Gough et al 2013 (BEGIN: Low Volume)
Insulin-naïve adults with type 2 diabetes starting on Tresiba® U-200, 26-week study
Gough SCL, Bhargava A, Jain R, Mersebach H, Rasmussen S, Bergenstal RM. Diabetes Care. 2013;36(9):2536-2542.


Meneghini et al 2013 (BEGIN: FLEX T2)
Adults with type 2 diabetes inadequately controlled on basal insulin alone, oral antidiabetic drugs (OADs) alone, or both basal insulin and OADs, 26-week study
Meneghini L, Atkin SL, Gough SCL, et al; on behalf of the NN1250-3668 (BEGIN FLEX) Trial Investigators. Diabetes Care. 2013;36(4):858-864.

